Strata Critical Medical, Inc. (SRTA) Stock Analysis and Metrics

Strata Critical Medical

NASDAQ: SRTA

$5.14 ▼ -0.09 (-1.82%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap450.51 Mn

P/E7.55

P/S1.77

Div. Yield0.00

ROIC (Qtr)0.00

Revenue Growth (1y) (Qtr)87.45

Add ratio to table…

About

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations offering an integrated one call solution for donor organ recovery. Core services include air and ground logistics surgical organ recovery organ placement and normothermic regional perfusion for the transplant industry as well as perfusion staffing and equipment solutions for cardiovascular surgery centers offered under the Trinity Medical Solutions and Keystone Perfusion brands.

Strata generates revenue by providing logistics and clinical services to transplant centers organ procurement organizations hospitals and other healthcare businesses. Logistics services include air and ground transportation of human organs for transplant as well as related staff equipment blood samples and tissue samples. Clinical services consist of surgical organ recovery normothermic regional perfusion organ placement cardiac care perfusion blood management autotransfusion disposables extracorporeal membrane oxygenation services perfusion temporary staffing and equipment rental. Revenue is primarily derived from fee-for-service arrangements with some clinical services also billed on a retainer basis.

Strata operates in a single segment offering a variety of logistics and clinical services related to organ transplant and the broader healthcare industry.

Strata holds a significant position within the organ transplant logistics and medical services industry due to its integrated one call solution combining air and ground logistics with clinical capabilities such as surgical recovery and normothermic regional perfusion. The Company competes with providers offering proprietary organ preservation technology additional clinical capabilities or ground and commercial air transport alternatives. Competitive advantages include its asset-light air logistics model utilizing third-party operators capacity purchase agreements and owned aircraft in high-volume geographies its integration of logistics and clinical services to streamline communication and transportation and its proprietary technology for staffing training and chain of custody management.

Strata serves transplant centers organ procurement organizations hospitals and other healthcare businesses across the United States. The Company relies on contractual relationships with these entities which pay Strata directly for its services. Specific customer names are not disclosed in the filing but the customer base includes entities involved in heart liver lung and kidney transplant programs as well as cardiovascular surgery centers requiring perfusion support.

Investment Thesis

▲ Bull case

SRTA's hybrid logistics and clinical model is creating a defensible moat in the organ transplant ecosystem, particularly through the integration of third-party surgical recovery and Normothermic Regional Perfusion (NRP), which management indicated is now performed on over half of all Donation after Circulatory Death (DCD) donors, a trend that is accelerating yields per donor and offsetting prior declines in donor volume. This structural shift, driven by regulatory and operational pressures on transplant centers to outsource complex recoveries, positions SRTA as an indispensable partner rather than a vendor, with the company actively expanding its national footprint of 20 logistics hubs and a new integrated Chicago base that enables local surgeon deployment and reduces costly dry runs by more than 25% in DCD cases. The company's ability to cross-sell Clinical services to existing Logistics clients—evidenced by onboarding new Transplant Center customers who are already logistics customers—creates a high-margin, recurring revenue flywheel that is underappreciated by the market, which remains focused on headline Logistics growth while overlooking the higher-margin, scalable Clinical segment that posted 25% gross margin in Q1 2026 and is trending above expectations due to a favorable mix shift toward Transplant Clinical services.
SRTA's capital allocation strategy is significantly under-leveraged relative to its opportunity set, with $58.8 million in cash, an undrawn $30 million ABL facility (expandable to $50 million), and up to $45 million in potential Joby earn-out payments providing substantial dry powder for accretive M&A, yet the market fails to recognize the company's proven ability to acquire targets at mid-single-digit EBITDA multiples—demonstrated by the $1 million Ohio Valley Perfusion Associates acquisition expected to generate $100,000 in adjusted EBITDA for the remainder of 2026—while management explicitly signaled an active pipeline of larger bolt-ons capable of generating low single-digit millions of adjusted EBITDA annually. This disciplined, platform-enhancing M&A approach, prioritizing strategic fit over financial arbitrage, is further strengthened by SRTA's status as the "acquirer of choice" for founder-led businesses seeking liquidity and scale through publicly traded equity, a dynamic that reduces integration risk and accelerates synergies, yet the market continues to value the company primarily on organic Logistics growth, ignoring the tangible, near-term EBITDA accretion from its under-the-radar acquisition engine.
Despite sequential Logistics revenue declining 3.3% in Q1 2026 due to customer mix and winter airport closures, SRTA's underlying Logistics business demonstrated resilience through 32.4% organic year-over-year growth, with management clarifying that the sequential dip was driven by temporary, non-structural factors—specifically a shift toward shorter-haul OPO customers and seasonal weather disruptions—and emphasizing that organ transport distances have increased approximately 60% over the past five years due to regulatory allocation policy changes, a long-term trend that will benefit SRTA's asset-intensive, nationwide aviation platform as transplant centers increasingly rely on third-party logistics for longer, more complex recoveries. The company's fuel pass-through mechanism, embedded in customer contracts, effectively insulates margins from volatile oil prices, a point reinforced by management's explicit statement that fuel cost inflation has "limited business impact," yet the market appears to be over-indexing on near-term Logistics margin pressure while disregarding the structural tailwinds from increasing transport distances and the scalability of SRTA's owned fleet (now 10 aircraft) and dedicated ground resources, which reduce repositioning costs and improve asset utilization as density increases in key markets like Chicago.

SRTA's hybrid logistics and clinical model is creating a defensible moat in the organ transplant ecosystem, particularly through the integration of third-party surgical recovery and Normothermic Regional Perfusion (NRP), which management indicated is now performed on over half of all Donation after Circulatory Death (DCD) donors, a trend that is accelerating yields per donor and offsetting prior declines in donor volume. This structural shift, driven by regulatory and operational pressures on transplant centers to outsource complex recoveries, positions SRTA as an indispensable partner rather than a vendor, with the company actively expanding its national footprint of 20 logistics hubs and a new integrated Chicago base that enables local surgeon deployment and reduces costly dry runs by more than 25% in DCD cases. The company's ability to cross-sell Clinical services to existing Logistics clients—evidenced by onboarding new Transplant Center customers who are already logistics customers—creates a high-margin, recurring revenue flywheel that is underappreciated by the market, which remains focused on headline Logistics growth while overlooking the higher-margin, scalable Clinical segment that posted 25% gross margin in Q1 2026 and is trending above expectations due to a favorable mix shift toward Transplant Clinical services.
SRTA's capital allocation strategy is significantly under-leveraged relative to its opportunity set, with $58.8 million in cash, an undrawn $30 million ABL facility (expandable to $50 million), and up to $45 million in potential Joby earn-out payments providing substantial dry powder for accretive M&A, yet the market fails to recognize the company's proven ability to acquire targets at mid-single-digit EBITDA multiples—demonstrated by the $1 million Ohio Valley Perfusion Associates acquisition expected to generate $100,000 in adjusted EBITDA for the remainder of 2026—while management explicitly signaled an active pipeline of larger bolt-ons capable of generating low single-digit millions of adjusted EBITDA annually. This disciplined, platform-enhancing M&A approach, prioritizing strategic fit over financial arbitrage, is further strengthened by SRTA's status as the "acquirer of choice" for founder-led businesses seeking liquidity and scale through publicly traded equity, a dynamic that reduces integration risk and accelerates synergies, yet the market continues to value the company primarily on organic Logistics growth, ignoring the tangible, near-term EBITDA accretion from its under-the-radar acquisition engine.
Despite sequential Logistics revenue declining 3.3% in Q1 2026 due to customer mix and winter airport closures, SRTA's underlying Logistics business demonstrated resilience through 32.4% organic year-over-year growth, with management clarifying that the sequential dip was driven by temporary, non-structural factors—specifically a shift toward shorter-haul OPO customers and seasonal weather disruptions—and emphasizing that organ transport distances have increased approximately 60% over the past five years due to regulatory allocation policy changes, a long-term trend that will benefit SRTA's asset-intensive, nationwide aviation platform as transplant centers increasingly rely on third-party logistics for longer, more complex recoveries. The company's fuel pass-through mechanism, embedded in customer contracts, effectively insulates margins from volatile oil prices, a point reinforced by management's explicit statement that fuel cost inflation has "limited business impact," yet the market appears to be over-indexing on near-term Logistics margin pressure while disregarding the structural tailwinds from increasing transport distances and the scalability of SRTA's owned fleet (now 10 aircraft) and dedicated ground resources, which reduce repositioning costs and improve asset utilization as density increases in key markets like Chicago.

▼ Bear case

SRTA's Clinical segment, while showing strong sequential growth and margin expansion to 25% in Q1 2026, remains highly dependent on the successful integration and scaling of its transplant clinical services, with management acknowledging that the current gross margin level is "not expected to remain that high every quarter" due to potential variability in case mix and the early-stage nature of the business, which only emerged post-Keystone acquisition and lacks the multi-year historical data to validate the sustainability of its current profitability trajectory, creating a risk that the market is overestimating the durability of Clinical's contribution to consolidated earnings as the company transitions from a logistics-focused model to a more complex, clinically integrated offering.
The company's reliance on earn-out payments from the Joby Passenger business sale—potentially up to $45 million—introduces significant uncertainty to its balance sheet and future liquidity, as these payments are contingent on Blade's financial performance post-close and employee retention milestones, with up to $17.5 million due by end of August 2026 and the remainder tied to former Blade employees transferring to Joby, a structure that exposes SRTA to counterparty risk and potential clawbacks if performance targets are not met, yet the market appears to be treating this contingent consideration as near-certain cash inflow when allocating capital for M&A and shareholder returns, overlooking the inherent variability and potential delays in realization that could constrain the company's ability to fund its stated acquisition pipeline or support its capital expenditure plans for fleet expansion and infrastructure buildout.
SRTA's Logistics gross margin pressure, which declined 220 basis points sequentially from Q4 2025 to 19.3% in Q1 2026 due to a shift toward lower-margin OPO customers and customer mix changes, may reflect deeper, structural challenges in the organ logistics market that management is downplaying as "normal quarter-to-quarter variability," particularly as the company acknowledged that OPOs typically yield shorter trip lengths and require smaller aircraft types, which inherently limit revenue per flight and increase fixed cost allocation per unit, a dynamic that could persist if the industry's shift toward DCD donations continues to favor localized recovery and transport networks, undermining SRTA's asset-heavy, nationwide aviation model and potentially forcing a strategic reevaluation of its Logistics segment's long-term profitability, a risk the market is ignoring by focusing solely on the company's top-line growth and cash generation while overlooking the deteriorating unit economics in its core Logistics business.

SRTA's Clinical segment, while showing strong sequential growth and margin expansion to 25% in Q1 2026, remains highly dependent on the successful integration and scaling of its transplant clinical services, with management acknowledging that the current gross margin level is "not expected to remain that high every quarter" due to potential variability in case mix and the early-stage nature of the business, which only emerged post-Keystone acquisition and lacks the multi-year historical data to validate the sustainability of its current profitability trajectory, creating a risk that the market is overestimating the durability of Clinical's contribution to consolidated earnings as the company transitions from a logistics-focused model to a more complex, clinically integrated offering.
The company's reliance on earn-out payments from the Joby Passenger business sale—potentially up to $45 million—introduces significant uncertainty to its balance sheet and future liquidity, as these payments are contingent on Blade's financial performance post-close and employee retention milestones, with up to $17.5 million due by end of August 2026 and the remainder tied to former Blade employees transferring to Joby, a structure that exposes SRTA to counterparty risk and potential clawbacks if performance targets are not met, yet the market appears to be treating this contingent consideration as near-certain cash inflow when allocating capital for M&A and shareholder returns, overlooking the inherent variability and potential delays in realization that could constrain the company's ability to fund its stated acquisition pipeline or support its capital expenditure plans for fleet expansion and infrastructure buildout.
SRTA's Logistics gross margin pressure, which declined 220 basis points sequentially from Q4 2025 to 19.3% in Q1 2026 due to a shift toward lower-margin OPO customers and customer mix changes, may reflect deeper, structural challenges in the organ logistics market that management is downplaying as "normal quarter-to-quarter variability," particularly as the company acknowledged that OPOs typically yield shorter trip lengths and require smaller aircraft types, which inherently limit revenue per flight and increase fixed cost allocation per unit, a dynamic that could persist if the industry's shift toward DCD donations continues to favor localized recovery and transport networks, undermining SRTA's asset-heavy, nationwide aviation model and potentially forcing a strategic reevaluation of its Logistics segment's long-term profitability, a risk the market is ignoring by focusing solely on the company's top-line growth and cash generation while overlooking the deteriorating unit economics in its core Logistics business.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password